The Impact of HBV Therapy on Fibrosis and Cirrhosis

In this CME-certified module, Jordan J. Feld, MD, MPH, provides guidance on strategies to reverse liver fibrosis and cirrhosis with oral antiviral agents in patients with chronic hepatitis B.
Jordan J. Feld, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: December 30, 2016 Expiration: December 29, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement HBV counseling and treatment strategies that reflect the ability of therapy to prevent and reverse fibrosis and cirrhosis
  • Apply current management guidelines when managing patients infected with HBV

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an independent educational grant from
Gilead Sciences

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck and consulting fees from AbbVie, Gilead Sciences, Janssen, and Merck.

Staff

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc, ELS

Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hepatologists, gastroenterologists, infectious disease physicians, and other healthcare professionals involved in the management of patients infected with HBV.

Goal

The goal of this activity is to improve participants’ competence in implementing strategies to reverse liver fibrosis and cirrhosis using oral anti-HBV agents.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 30, 2016, through December 29, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

CME-certified expert panel discussion of controversial issues in the management of HBV and HCV infection.

Norah Terrault, MD, MPH
Program Director
Paul Martin, MD Christian B. Ramers, MD, MPH Nancy Reau, MD, FAASLD, AGAF
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: July 6, 2018 Expiration: July 5, 2019

Expert HBV management review, including treatment candidacy, preferred treatment options, and antiviral resistance and advanced liver disease management.

Stefan Zeuzem, MD
Program Director
Harry L. A. Janssen, MD, PhD Milan J. Sonneveld, MD, PhD, MSc
Released: June 21, 2018

When and how to treat hepatitis B infection in women of childbearing age, in early pregnancy, and in late pregnancy.

Natalie H. Bzowej, MD, PhD Released: June 8, 2018

In this downloadable slideset, expert faculty provide a comprehensive update on managing HCV in special patient populations.

Jordan J. Feld, MD, MPH Nancy Reau, MD, FAASLD, AGAF Mark S. Sulkowski, MD Released: May 29, 2018

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?